|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||144.75 - 144.75|
|52 Week Range||100.00 - 150.00|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||168.50|
Companies that have significant growth prospects for profitability and returns can add tangible upside to your portfolio. Oncimmune Holdings and APQ Global are examples of many potential outperformers that analystsRead More...
DESOTO, Kan., Nov. 9, 2017 /PRNewswire/ -- Oncimmune USA LLC, the U.S. subsidiary of Oncimmune Holdings plc (AIM:ONC.L), a leading early cancer detection company developing and commercializing its proprietary EarlyCDT® platform technology, today announces its launch of a validated finger stick collection capability for its EarlyCDT®-Lung test. The EarlyCDT®-Lung test is a simple blood test that aids pulmonologists and other physicians in risk assessment and can detect lung cancer up to four years earlier than other methods. It is also highly cost-effective. "By introducing finger stick blood collection, we have created an option that will increase the speed and simplicity with which the EarlyCDT®-Lung test can be ordered and completed with no loss of performance.